Cite
Regula JT, Lundh von Leithner P, Foxton R, et al. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2017;9(7):985doi: 10.15252/emmm.201707895.
Regula, J. T., Lundh von Leithner, P., Foxton, R., Barathi, V. A., Gemmy Cheung, C. M., Bo Tun, S. B., Wey, Y. S., Iwata, D., Dostalek, M., Moelleken, J., Stubenrauch, K. G., Nogoceke, E., Widmer, G., Strassburger, P., Koss, M. J., Klein, C., Shima, D. T., & Hartmann, G. (2017). Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO molecular medicine, 9(7), 985. https://doi.org/10.15252/emmm.201707895
Regula, Jörg T, et al. "Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases." EMBO molecular medicine vol. 9,7 (2017): 985. doi: https://doi.org/10.15252/emmm.201707895
Regula JT, Lundh von Leithner P, Foxton R, Barathi VA, Gemmy Cheung CM, Bo Tun SB, Wey YS, Iwata D, Dostalek M, Moelleken J, Stubenrauch KG, Nogoceke E, Widmer G, Strassburger P, Koss MJ, Klein C, Shima DT, Hartmann G. Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med. 2017 Jul;9(7):985. doi: 10.15252/emmm.201707895. PMID: 28533211; PMCID: PMC5494529.
Copy
Download .nbib